Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Gestational Trophoblastic Neoplasia, Version 2.2019 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Abu-Rustum, N. R., Yashar, C. M., Bean, S., Bradley, K., Campos, S. M., Chon, H., Chu, C., Cohn, D., Crispens, M., Damast, S., Dorigo, O., Eifel, P. J., Fisher, C. M., Frederick, P., Gaffney, D. K., Han, E., Huh, W. K., Lurain, J. R., Mariani, A., Mutch, D., Nagel, C., Nekhlyudov, L., Fader, A., Remmenga, S. W., Reynolds, R., Sisodia, R., Tillmanns, T., Ueda, S., Wyse, E., McMillian, N. R., Scavone, J. 2019; 17 (11): 1374–91

Abstract

Gestational trophoblastic neoplasia (GTN), a subset of gestational trophoblastic disease (GTD), occurs when tumors develop in the cells that would normally form the placenta during pregnancy. The NCCN Guidelines for Gestational Trophoblastic Neoplasia provides treatment recommendations for various types of GTD including hydatidiform mole, persistent post-molar GTN, low-risk GTN, high-risk GTN, and intermediate trophoblastic tumor.

View details for DOI 10.6004/jnccn.2019.0053

View details for Web of Science ID 000499645400011

View details for PubMedID 31693991